CNM-Au8 Slows Disease Progression in Limb, Bulbar Onset ALS

CNM-Au8 Slows Disease Progression in Limb, Bulbar Onset ALS

313589

CNM-Au8 Slows Disease Progression in Limb, Bulbar Onset ALS

CNM-Au8, an investigational disease-modifying therapy for people with early amyotrophic lateral sclerosis (ALS), showed consistent clinical benefits in patients with both limb and bulbar onset disease, according to new analyses of RESCUE-ALS Phase 2 clinical trial data. In particular, the treatment significantly extended the time to disease progression — defined as death from any cause, or the need for tracheostomy, non-invasive ventilation, or a gastrostomy tube — in patients from both groups. It also was similarly…

You must be logged in to read/download the full post.